Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ACACA | Q13085 | 3/20 | 0.32 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 2/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16403611 | 0.95 | SUCNR1 (0.45) | SUCNR1JAK2JAK1HDAC1CFD | |
| SCHEMBL16410368 | 0.84 | HDAC1 (0.44) | SUCNR1JAK2JAK1HDAC1CFD | |
| SCHEMBL16403605 | 0.82 | CFD (0.46) | SUCNR1JAK2JAK1CFDKCNJ6 | |
| SCHEMBL17764462 | 0.79 | SUCNR1 (0.48) | SUCNR1HDAC1CFDNAMPT | |
| SCHEMBL16396451 | 0.79 | HDAC1 (0.44) | SUCNR1HDAC1CFDNAMPT | |
| SCHEMBL16410357 | 0.77 | HDAC1 (0.41) | SUCNR1HDAC1CFDNTRK1NAMPT | |
| SCHEMBL16410451 | 0.76 | DDR2 (0.43) | SUCNR1HDAC1CFD | |
| SCHEMBL16410285 | 0.76 | SMN1; SMN2 (0.42) | SUCNR1HDAC1 | |
| SCHEMBL16410326 | 0.75 | HDAC1 (0.36) | SUCNR1HDAC1ACACBACACACYP1A2 | |
| SCHEMBL16410322 | 0.74 | CFD (0.48) | SUCNR1HDAC1CFDNTRK1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | SUCNR1 4670/4885JAK2 4308/4885JAK1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.